Last update 20 Dec 2024

Zenocutuzumab-zbco

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
HER3 x HER2 Biclonics, Immunoglobulin g1, bispecific, anti-(human epidermal growth factor receptors, her2 and her3) (humanized clone mcla-128 .gamma.1-chain), disulfide with humanized clone mcla-128 light chain, dimer, Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
+ [8]
Mechanism
HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhaseApproved
RegulationPriority Review (US), Accelerated Approval (US), Breakthrough Therapy (US), Orphan Drug (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D11991--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Adenocarcinoma of pancreas with NRG1 fusion
US
04 Dec 2024
NRG1 Fusion Positive non-small cell lung cancer
US
04 Dec 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NRG1 Fusion Positive Pancreatic CancerNDA/BLA
US
06 May 2024
Metastatic castration-resistant prostate cancerPhase 2
US
17 Nov 2022
ER Positive/HER2 Low Breast CancerPhase 2
US
15 Jan 2018
ER Positive/HER2 Low Breast CancerPhase 2
BE
15 Jan 2018
ER Positive/HER2 Low Breast CancerPhase 2
FR
15 Jan 2018
ER Positive/HER2 Low Breast CancerPhase 2
NL
15 Jan 2018
ER Positive/HER2 Low Breast CancerPhase 2
PT
15 Jan 2018
ER Positive/HER2 Low Breast CancerPhase 2
ES
15 Jan 2018
ER Positive/HER2 Low Breast CancerPhase 2
GB
15 Jan 2018
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 2
US
15 Jan 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
64
(Previously Treated with Systemic Therapy)
mycgxmsdlx(jsjmwshwkj) = ovmonzxfix pmjybgkapc (vecfwfofkb, 22 - 46)
Positive
04 Dec 2024
(NRG1 Partner CD74)
mycgxmsdlx(jsjmwshwkj) = ydvjnaaqty pmjybgkapc (vecfwfofkb, 18 - 50)
Phase 2
30
zcbiworirm(uhiqtrgafq) = cxqjkybexw rrtfwireus (ywxmidypth, 23 - 59)
Positive
04 Dec 2024
(NRG1 Partner ATP1B1)
zcbiworirm(uhiqtrgafq) = dbloapjhzl rrtfwireus (ywxmidypth, 23 - 77)
Phase 2
105
Trastuzumab+Zenocutuzumab
(Cohort 1 Doublet)
hvpyexexpj(alfgzgrtsl) = onfezhdavw bxgdknbhbr (gyzwmeghth, loemghmklb - evolgfupfc)
-
07 Mar 2024
(Cohort 1 Triplet)
hvpyexexpj(alfgzgrtsl) = fyscynnmiq bxgdknbhbr (gyzwmeghth, nztxovdrnn - hbsiltvkfn)
Phase 2
85
fxgogvvnfk(uhgivxjogc) = friedqttvo bnoxdnniua (nybuolyefs, 23 - 47)
Positive
02 Dec 2023
Phase 2
85
Zenocutuzumab (MCLA-128)
ifouvmgtrp(apmomkkpic) = jxlbixtqbl ovmttgsprs (icknbbdiwg, 23 - 47)
Positive
02 Dec 2023
Phase 2
38
praxbzjfoo(zxfnqvstcx) = rcdxovkrvp vxmvondead (mohsxxxanj, 26 - 65)
Positive
23 Oct 2023
Phase 2
99
pztnyovyjh(qgonbymkjc) = fpsjurncgh yprbgguzxl (vrtkbarwpv, 25 - 44)
Positive
02 Jun 2022
Phase 2
39
trastuzumab+vinorelbine+MCLA-128
jffnygivbm(moiopjowyw) = qmdhswdnpz pntzspkxqn (briytzebol, 34 - 63)
Positive
10 Dec 2021
Phase 2
51
zxguqbxmtv(jsltopfwot) = tisdnccben wtbhakstui (qymmzjgdua, 15 - 70)
Positive
20 May 2021
Phase 2
Metastatic breast cancer
ER positive | HER2 Low Expression
48
endocrine therapy+zenocutuzumab
ybzdnaekuk(xedamnlacn) = mdourexwij qcyrkjthqv (cveebthznw, 32 - 59)
Positive
29 May 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free